Angelica M. Gutierrez‐Barrera

The paper identifies a metabolic vulnerability in triple-negative breast cancer through sphingolipid metabolism, showing that targeting this pathway with eliglustat reduces tumor growth and improves survival.

This study uses chaperone interactions to predict pathogenicity and cancer risk in BRCA1 mutation carriers by assessing structural and phenotypic defects.